The Power of Community-Driven Innovations in MedTech

Carla du Toit, a trained Kinesiologist, embarked on her graduate studies at Western University, where she unexpectedly found herself on an entrepreneurial journey that would lead to her becoming the CEO of a MedTech company, NovaSonix. Initially seeking a lab opportunity, Carla connected with Dr. Emily Lalone and Dr. Aaron Fenster, both esteemed professors at the university specializing in medical imaging and biomechanics. Together, they collaborated on a groundbreaking project aimed at revolutionizing ultrasound imaging technology, ultimately laying the groundwork for NovaSonix.

Their work culminated in the innovation of NovaVue, a comprehensive 3D ultrasound scanning device engineered to detect imaging biomarkers related to early-stage osteoarthritis—a significant development considering traditional treatments often come too late. Unlike standard X-rays, which cannot adequately assess soft tissue or detect early signs of osteoarthritis, NovaVue promises earlier diagnosis and effective monitoring, offering a portable and cost-effective alternative to more cumbersome methods like MRI.

As their idea transformed into a viable product, Carla chose to return to medical school in 2024, passing leadership responsibilities to Randa Mudathir, who now serves as CEO. The NovaSonix team expanded to include additional graduate students who became pivotal in developing the device. Their formative phase saw the team initially referred to as RCM Sonic Solutions, where they received early validation by winning a $30,000 prize at Western’s Bone and Joint Institute MSK Innovation Competition in 2023. This recognition facilitated their incorporation as NovaSonix Healthcare, marking a significant milestone in their business journey.

The methodical approach they adopted for product development involved extensive clinical research to identify unique opportunities in healthcare—an approach that diverges from traditional startup methodologies. By leveraging resources and guidance through the BioNext MedTech incubator at the Robarts Research Institute, NovaSonix gained access to federal grants and resources essential for early-stage commercialization efforts.

Despite the challenges inherent in launching a startup within the demanding MedTech sector, NovaSonix benefited from a robust support ecosystem, including mentorship from established advisors, enabling them to navigate various complexities associated with product development and market entry. They gained traction through accolades and funding opportunities that bolstered their confidence in the viability of their technology.

As they continue refining their product, the future outlook for NovaSonix is optimistic. The scalability of their platform technology allows for potential applications beyond musculoskeletal conditions, necessitating further regulatory approvals to expand their scope. The foundation built upon innovative partnerships and strong research output positions them favorably in a competitive landscape.

NovaSonix’s recent successes, such as their win at TechAlliance’s Polaris Pitch Competition, further validate their innovative approach and market readiness. The journey of NovaSonix embodies the synergy of collaboration, research, and resilience, showcasing how new technologies like NovaVue can reshape osteoarthritis diagnosis and treatment. As they advance towards commercialization, they hold promise for transforming the MedTech arena in Canada and beyond.